Cannabidiolic Acid (CBDA)

is similar to THCA and is the main constituent in cannabis when CBD levels are elevated.  CBDA selectively inhibits the COX-2 enzyme, contributing to cannabis’ anti-inflammatory effects.

Cannabidiol (CBD)

has tremendous medical potential. This is particularly true when the correct ratio of CBD to THC is applied to treat a particular condition. CBD acts as an antagonist at both the CB1 and CB2 receptors, yet it has a low binding affinity for both. This suggests that CBD’s mechanism of action is mediated by other receptors in the brain and body.

Cannabinol (CBN)

is a mildly psychoactive cannabinoid that is produced from the degradation of THC. There is usually very little to no CBN in a fresh plant. CBN acts as a weak agonist at both the CB1 and CB2 receptors, with greater affinity for CB2 receptors than CB1. The degradation of THC into CBN is often described as creating a sedative effect.

Cannabigerol (CBG)

is a non-psychoactive cannabinoid, CBG’s antibacterial effects may alter the overall effects of cannabis. CBG is known to slow bacterial growth, reduce inflammation, (particularly in its acidic CBGA form,) inhibit cell growth in cancer cells, and promote bone growth. It acts as a low-affinity antagonist at the CB1 receptor. CBG pharmacological activity at the CB2 receptor is currently unknown.

Cannabichromene (CBC)

is most frequently found in tropical cannabis varieties. CBC is known to relieve pain, reduce inflammation, inhibit cell growth in cancer cells, and promote bone growth. The effects of CBC appear to be mediated.